Skip to main content
. 2019 Jun 7;98(23):e15948. doi: 10.1097/MD.0000000000015948

Figure 2.

Figure 2

The prognostic impact of the relative fluorescence intensity (RFI) of CXCR4 expression in AML patients. A: overall survival (OS) in all AML patients. B: Disease-free survival (DFS) in all AML patients. C: OS in non-M3-AML patients. D: DFS in non-M3-AML patients. E: OS in all relapsed AML patients. The P values were determined using the log-rank test. Survival analyses were performed by Kaplan–Meier methods. CXCR4 = CXC chemokine receptor 4.